Integra LifeSciences IART Payment for Contingent Consideration Liability, Financing Activities

Payment for Contingent Consideration Liability, Financing Activities at other companies

Henry ScheinHSIC

$0-100%

Merit Medical SystemsMMSI

——

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's payment for contingent consideration liability, financing activities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's payment for contingent consideration liability, financing activities?: Integra LifeSciences (IART) reported payment for contingent consideration liability, financing activities of $0 in Q1 2026.
How has Integra LifeSciences's payment for contingent consideration liability, financing activities changed year-over-year?: Integra LifeSciences's payment for contingent consideration liability, financing activities decreased by 100.0% year-over-year, from $2.6M to $0.